Project Grant R01CA308828
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $512K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Richmond, VA 23298, USA
Similar Awards
- Federal Project Grant Award Summary Virginia Commonwealth University received a $634,062 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), awarded June 5, 2026, with completion targeted for May 31, 2031. The award funds research on atypical sphingolipids in hepatocellular carcinoma (HCC), a leading cause of cancer-related death. The research will investigate the role of serine palmitoyltransferase long-chain base subunit 3 (SPTLC3), a novel...
- Federal Project Grant Summary Virginia Commonwealth University received a $399,187 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on May 7, 2026, with completion scheduled for April 30, 2028. This translational exploratory/developmental research project focuses on developing a theragnostic approach utilizing glycosaminoglycans (GAGs)—specifically heparan sulfate and chondroitin sulfate—to overcome platinum resistance in...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $403,586 Project Grant from the National Cancer Institute (Cancer Biology Research program, CFDA 93.396) beginning August 1, 2025, and concluding July 31, 2027. The award supports research to develop codon-specific isotope labeling technology for nuclear magnetic resonance (NMR) resonance assignment. This novel methodology addresses critical obstacles in characterizing intrinsically disordered proteins (IDPs),...
- Federal Project Grant Award Summary Virginia Commonwealth University received a $399,187 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective July 1, 2026 through June 30, 2028. The award supports research to explore a novel therapeutic approach targeting advanced prostate cancer, specifically castration-resistant prostate cancer (CRPC) that has developed resistance to enzalutamide (ENZ), a frontline treatment agent. The...
- Federal Grant Award Summary Virginia Commonwealth University received a $1.79M Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded September 1, 2025, with completion targeted for August 31, 2029. The research project, "Targeting Ganglioside GD2 to Overcome Chemotherapy Resistance in Triple-Negative Breast Cancer," focuses on developing innovative therapeutic approaches to address chemotherapy resistance in...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG). The award, effective April 1, 2026 through March 31, 2028, supports the development and characterization of novel humanized TROP2 mouse...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
- Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...
- Federal Grant Award Summary The National Cancer Institute awards $161,500 to the University of Virginia under the Cancer Biology Research program (CFDA 93.396) for a two-year project (June 1, 2026–May 31, 2028) focused on advancing detection and classification of circulating tumor cells (CTCs) from pancreatic ductal adenocarcinoma (PDAC) patients. The project develops complementary biophysical metrics to immunofluorescence imaging by leveraging single-cell deformability analysis to identify...
- Federal Grant Award Summary The University of Virginia received a $415,257 Project Grant from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), effective July 1, 2026 through June 30, 2028. The grant funds development of a comprehensive intervention to address financial toxicity (FT)—a multidimensional construct encompassing material burden, psychosocial distress, and coping behaviors driven by financial strain—among cancer survivors and...